Want to see COCH full AI Analyst Report?

Envoy Medical (COCH) Price & Analysis

127 Followers

COCH Stock Chart & Stats

$0.66

>-$0.01(-1.13%)

At close: Jul 27 4:00 PM EDT

$0.66

>-$0.01(-1.13%)

Day’s Range― - ―

52-Week Range$0.36 - $1.89

Previous CloseN/A

Volume100.00

Average Volume (3M)394.38K

Market Cap

$61.76M

Enterprise Value$63.53

Total Cash (Recent Filing)$19.68M

Total Debt (Recent Filing)$810.00K

Price to Earnings (P/E)―

Beta0.32

Next Earnings

Nov 18, 2026

EPS Estimate

-0.07

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.67

Shares Outstanding77,194,595

10 Day Avg. Volume193,663

30 Day Avg. Volume394,378

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)-1.31

Price to Sales (P/S)63.80

P/FCF Ratio-0.84

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$2.25

Price Target Upside240.91% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-0.29

Revenue Forecast (FY)$200.00K

Bulls Say, Bears Say

Bulls Say

Differentiated Implantable TechnologyEnvoy’s fully implanted approach (Esteem; investigational Acclaim) offers 24/7 hearing using natural anatomy, a structural product differentiation that can boost long-term adherence and clinician preference versus external devices. This durable advantage supports niche market penetration and recurring system-related sales if adoption expands.

Management Signals Near-Term Capital ConfidenceTerminating the $15M ATM program indicates management believes current resources suffice to advance the portfolio, reducing immediate dilution risk. Over 2-6 months this preserves equity optionality and gives runway to focus on commercialization and regulatory milestones without continual ATM issuance.

Low Reported Financial LeverageVery low reported debt provides structural financial flexibility and limited interest burden, important given ongoing cash needs. Lower fixed obligations reduce near-term solvency pressure and can ease negotiations with lenders or partners, supporting sustained R&D and commercialization efforts if cash is secured.

Bears Say

Severe Cash BurnSustained ~-$21.5M TTM cash outflow implies the business cannot self-fund operations or commercialization and is structurally dependent on external capital. Over the medium term this elevates dilution and refinancing risk, constrains marketing/clinical investments, and can force strategic trade-offs if funding access tightens.

Minimal Revenue With Negative Gross ProfitTiny, declining revenue and negative gross margin show the company isn’t covering direct product costs at current scale. Without meaningful adoption or pricing/cost improvements, the commercial model lacks unit economics to support operating overhead, threatening long-term viability absent scale or structural changes.

Listing Pressure And Increased Dilution CapacityA Nasdaq bid-price extension signals persistent listing risk that may force structural actions (reverse split). Concurrent shareholder approval to add 7.2M shares raises medium-term dilution capacity. Together these factors impair investor confidence and can complicate fundraising terms, governance, and long-term share value support.

Envoy Medical News

Envoy Medical initiated with a Buy at Lucid Capital

Lucid Capital analyst Alex Nowak initiated coverage of Envoy Medical (COCH) with a Buy rating and $2 price...

21d ago

COCH

Envoy Medical’s Limited Disclosures Put Spotlight on 10-K Risk Factors for Investors

Envoy Medical, Inc. Class A (COCH) has disclosed a new risk, in the Regulation category. Envoy Medical, Inc....

7d ago

COCH

Envoy Medical Ends ATM Equity Program Amid Capital Confidence

Envoy Medical ( ($COCH) ) has provided an update. Envoy Medical, Inc., a Nasdaq-listed hearing health company, develops...

2M ago

COCH

Envoy Medical signs multi-part series with New to The Street

Envoy Medical (COCH) has signed a multi-part national media series with New to The Street. The campaign is...

3M ago

COCH

Envoy Medical Granted Extension to Regain Nasdaq Compliance

Envoy Medical ( ($COCH) ) just unveiled an announcement. Envoy Medical, Inc. disclosed that on November 19, 2025,...

3M ago

COCH

Envoy Medical Shareholders Expand Equity and Governance Plans

Envoy Medical ( ($COCH) ) has provided an announcement. At its May 12, 2026 annual meeting, Envoy Medical...

3M ago

COCH

COCH Upcoming Earnings Report: What to Expect?

Envoy Medical, Inc. Class A (COCH) is scheduled to report 1st quarter earnings on 05/20/2026, before the market...

3M ago

COCH

Envoy Medical Flags Limited Risk Detail, Urges Investors to Review 2026 Form 10-K for Key Uncertainties

Envoy Medical, Inc. Class A (COCH) has disclosed a new risk, in the Regulation category. Envoy Medical, Inc....

3M ago

COCH

Envoy Medical initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Envoy Medical (COCH) with a Buy rating and $2.50 price target Envoy is...

5M ago

COCH

Envoy Medical Regains Nasdaq Listing Compliance After Financing

Envoy Medical ( ($COCH) ) has issued an update. On February 24, 2026, Envoy Medical announced it had...

6M ago

COCH

Envoy Medical Closes Upsized Public Offering to Fund Growth

Envoy Medical ( ($COCH) ) just unveiled an announcement. On February 12, 2026, Envoy Medical announced the closing...

6M ago

COCH

Envoy Medical Grants Stock Options to Key Executives

Envoy Medical ( ($COCH) ) has provided an update. On February 5, 2026, Envoy Medical, Inc.’s compensation committee...

6M ago

COCH

Envoy Medical Extends Shortfall Warrants, Enhancing Capital Flexibility

The latest announcement is out from Envoy Medical ( ($COCH) ). On December 18, 2025, Envoy Medical, Inc....

8M ago

COCH

Envoy Medical files to sell Class A common stock, no amount given

17:22 EST Envoy Medical (COCH) files to sell Class A common stock, no amount given Published first on...

8M ago

COCH

COCH FAQ

What was Envoy Medical’s price range in the past 12 months?

Envoy Medical lowest stock price was $0.36 and its highest was $1.89 in the past 12 months.

What is Envoy Medical’s market cap?

Envoy Medical’s market cap is $61.76M.

When is Envoy Medical’s upcoming earnings report date?

Envoy Medical’s upcoming earnings report date is Nov 18, 2026 which is in 93 days.

How were Envoy Medical’s earnings last quarter?

Envoy Medical released its earnings results on Aug 10, 2026. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.08 by $0.01.

Is Envoy Medical overvalued?

According to Wall Street analysts Envoy Medical’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Envoy Medical pay dividends?

Envoy Medical does not currently pay dividends.

What is Envoy Medical’s EPS estimate?

Envoy Medical’s EPS estimate is -0.07.

How many shares outstanding does Envoy Medical have?

Envoy Medical has 77,194,595 shares outstanding.

What happened to Envoy Medical’s price movement after its last earnings report?

Envoy Medical reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.08. Following the earnings report the stock price went up 5.067%.

Which hedge fund is a major shareholder of Envoy Medical?

Currently, no hedge funds are holding shares in COCH

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Envoy Medical Stock Smart Score

Underperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

141.91%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Envoy Medical

Envoy Medical, Inc. is a healthcare company dedicated to developing innovative medical technologies that address the full spectrum of hearing loss. Its diverse product portfolio includes conventional hearing aids, Esteem middle ear implants, bone conduction devices, and Acclaim cochlear implants. Established in 1995, the company originally operated as St. Croix Medical, Inc. before officially rebranding to Envoy Medical, Inc. in December 2004. Envoy Medical, Inc. is headquartered in White Bear Lake, Minnesota.

Envoy Medical (COCH) Earnings & Revenues

Historic Earnings Reports

COCH Stock 12 Month Forecast

Average Price Target

$2.25

▲(240.91% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","2":"$2","3":"$3","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.67,0.8107692307692308,0.9515384615384617,1.0923076923076924,1.2330769230769232,1.373846153846154,1.514615384615385,1.6553846153846155,1.7961538461538464,1.936923076923077,2.077692307692308,2.2184615384615385,2.3592307692307695,{"y":2.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.67,0.7915384615384615,0.9130769230769231,1.0346153846153847,1.1561538461538463,1.2776923076923077,1.3992307692307693,1.5207692307692309,1.6423076923076922,1.763846153846154,1.8853846153846154,2.006923076923077,2.1284615384615386,{"y":2.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.67,0.7723076923076924,0.8746153846153847,0.976923076923077,1.0792307692307692,1.1815384615384614,1.2838461538461539,1.3861538461538463,1.4884615384615385,1.5907692307692307,1.693076923076923,1.7953846153846156,1.8976923076923078,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.445,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.773,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.805,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.81,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.661,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.649,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.699,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.705,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.681,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.79,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.67,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >